Exchange: NASDAQ·Updated 07:30 PM EDT
MDGL logo

MDGL Madrigal Pharmaceuticals Inc

$457.96
$9.58
(2.05%)
Today
Closed $457.96
$0.00
(0.00%)
After Hours
EarningsNov 3
Mkt Cap$10.8B
Vol338,294.00

About MDGL

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of therapeutics for metabolic dysfunction-associated steatohepatitis. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.
51

Neutral Sentiment

How do you feel about MDGL?

BioEu
$MDGL ✅ These are just forecasts; I believe we will have to wait until the day the quarterly results are released, with the shares already trading in the 500–510 range.
5
BioEu
$MDGL ✅ After a long absence from Madrigal, I’m back. This pullback offers an excellent entry point, with the aim of capitalizing on the upcoming quarterly results—it’s a fantastic company, with solid revenue growth and no competitors at the moment. GO MADRIGAL!
6
timfris
$MDGL the only good news is that I’ve seen this happen before earnings only to skyrocket afterwords. Also, the drag on the SP would raise chances of a deal, IMO, as it would show a higher premium at buyout.
1
1
sarkar20
$MDGL Most of the times this kind if manipulation (without any news) is seen before BO!! Hope this is the case for MDGL too, BO soon?
1
2
forprofit12
$MDGL ER has mostly been a drag recently. Hopefully this time it would change. Have they announced ER as yet?
3
Wallst45
$MDGL CITI INITIATES MADRIGAL PHARMACEUTICALS COVERAGE WITH BUY RATING AND $725 PT The firm believes the company's Rezdiffra is being underappreciated at current share levels. The launch has exceeded expectations and "blockbuster status is imminent"
4
NON_FICTION_1
$MDGL 👈i wont post much here either. Less then 3 years this biotech gets buyout. Dont at me later. Another just load and hold. No trades.
3
balzofsteel
$MDGL Citigroup Initiates Coverage On Madrigal Pharmaceuticals with Buy Rating, Announces Price Target of $725 Benzinga 2026-09-23T11:04:00-04:00 Citigroup analyst Eric Joseph initiates coverage on Madrigal Pharmaceuticals (MDGL.NaE) with a Buy rating and announces Price Target of $725
3
Live2ride
$MDGL This is starting to feel like a last ditch effort to get retail traders shares before they let it rip into EOY. I think M&A picks up before Dec 31st.
2
Live2ride
$MDGL Back to buy zone for me. Not sure if a swing or core. Market may decide that for me.
2
forprofit12
$MDGL and? Price is still pathetic. Regret adding this. The lost opportunity cost on this one is huge.
2
forprofit12
$MDGL something not good. 2.7x volume and red is not a good sign. It is also trading at recent lows.
1
Whiskeyunderthebed
$MDGL Has nothing to do with it- sector rotation and money are leaving health care sector-
1
sarkar20
$MDGL I guess there is no BO and it seems not good things in future the way stock price is moving these days!!

Advertisement|Remove ads.